HSD17B13 variants and uses thereof

Patent metadata

Field	Value
Publication number	US-11845963-B2
Application number	US-201815875192-A
Country	US
Kind code	B2
Filing date	Jan 19, 2018
Priority date	Jan 23, 2017
Publication date	Dec 19, 2023
Grant date	Dec 19, 2023

Abstract

Provided are compositions related to HSD17B13 variants, including nucleic acid molecules and polypeptides related to variants of HSD17B13, and cells comprising those nucleic acid molecules and polypeptides. Also provided are methods related to HSD17B3 variants. Such methods include methods for detecting the presence of the HSD17B13 rs72613567 variant in a biological sample comprising genomic DNA, for detecting the presence or levels of any one of variant HSD17B13 Transcripts C, D, E, F, G, and H, and particularly D, in a biological sample comprising mRNA or cDNA, or for detecting the presence or levels of any one of variant HSD17B13 protein Isoforms C, D, E, F, G, or H, and particularly D, in a biological sample comprising protein. Also provided are methods for determining a subject's susceptibility to developing a liver disease or of diagnosing a subject with liver disease.

First claim

What is claimed is:

1. A cDNA molecule comprising a nucleotide sequence encoding a human Hydroxysteroid 17-Beta Dehydrogenase 13 polypeptide, wherein the nucleotide sequence comprises SEQ ID NO:24 or SEQ ID NO:33.

2. A vector comprising the nucleic acid molecule of claim 1 .

3. A cell comprising the nucleic acid molecule of claim 1 .

4. A probe molecule comprising a nucleotide sequence and a heterologous label, wherein the nucleotide sequence of the probe consists of 5 to 50 nucleotides, and the probe is hybridized to:
a) an HSD17B13 Transcript D having at least 95% sequence identity to the nucleotide sequence of SEQ ID NO:6 or 15; or
b) an HSD17B13 cDNA having at least 95% sequence identity to the nucleotide sequence of SEQ ID NO:24 or 33, or the complement thereof.

5. The probe molecule according to claim 4 , where the probe is hybridized to an HSD17B13 Transcript D having at least 95% sequence identity to the nucleotide sequence of SEQ ID NO:6.

6. The probe molecule according to claim 4 , where the probe is hybridized to an HSD17B13 Transcript D having at least 95% sequence identity to the nucleotide sequence of SEQ ID NO:15.

7. The probe molecule according to claim 4 , where the probe is hybridized to an HSD17B13 cDNA having at least 95% sequence identity to the nucleotide sequence of SEQ ID NO:24 or the complement thereof.

8. The probe molecule according to claim 4 , where the probe is hybridized to an HSD17B13 cDNA having at least 95% sequence identity to the nucleotide sequence of SEQ ID NO: 33 or the complement thereof.

9. The probe molecule according to claim 4 , wherein the probe is hybridized to an HSD17B13 Transcript D having the nucleotide sequence of SEQ ID NO:6.

10. The probe molecule according to claim 4 , wherein the probe is hybridized to an HSD17B13 Transcript D having the nucleotide sequence of SEQ ID NO:15.

11. The probe molecule according to claim 4 , wherein the probe is hybridized to an HSD17B13 cDNA having the nucleotide sequence of SEQ ID NO:24 or the complement thereof.

12. The probe molecule according to claim 4 , wherein the probe is hybridized to an HSD17B13 cDNA having the nucleotide sequence of SEQ ID NO:33 or the complement thereof.

Assignees

• Regeneron Pharma

Inventors

• Abul-Husn Noura S
• Gottesman Omri
• Li Alexander
• Cheng Xiping
• Xin Yurong
• Gromada Jesper
• Dewey Frederick E
• Baras Aris
• Shuldiner Alan

Classifications

• C12N15/907

  in mammalian cells · CPC title

• C12N9/22

  Ribonucleases {[RNase]; Deoxyribonucleases [DNase]} · CPC title

• C12N2310/531

  Stem-loop; Hairpin · CPC title

• C12N2310/20

  involving clustered regularly interspaced short palindromic repeats [CRISPR] · CPC title

• C12N2310/14

  interfering nucleic acids [NA] · CPC title